Combinations of cationic alpha-helical antimicrobial peptide and d-arginine or d-lysine for useagainst bacterial infections

Combining antimicrobial peptides with D-amino acids like D-arginine or D-lysine addresses antibiotic resistance and toxicity issues, offering a synergistic and cost-effective treatment for bacterial infections.

WO2026238990A1PCT designated stage Publication Date: 2026-11-19UNIVERSITEIT UTRECHT HOLDING BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/064257
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Conventional antibiotics face issues with antibiotic resistance and high costs, while antimicrobial peptides (AMPs) have high cytotoxicity and expense, necessitating a more effective and cost-effective treatment for bacterial infections.

Method used

Combining antimicrobial peptides with positively charged D-amino acids, such as D-arginine or D-lysine, to enhance bactericidal efficacy against multiple bacterial species, including resistant strains.

Benefits of technology

The combination achieves up to 100% bactericidal effect at concentrations where monotherapy is ineffective, providing a synergistic and cost-effective treatment for bacterial infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000037_0000
    Figure 00000037_0000
  • Figure 00000038_0000
    Figure 00000038_0000
  • Figure 00000038_0001
    Figure 00000038_0001
Patent Text Reader

Abstract

The invention relates to combinations of an antimicrobial peptide and a positively charged D-amino acid for use in the treatment or prevention of a bacterial infection in a subject, to pharmaceutical compositions comprising an antimicrobial peptide, a positively charged D-amino acid and a pharmaceutically acceptable carrier and / or excipient and to kits of parts comprising a pharmaceutical composition comprising an antimicrobial peptide and a pharmaceutically acceptable carrier and / or excipient, and a pharmaceutical composition comprising a positively charged D- amino acid and a pharmaceutically acceptable carrier and / or excipient.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] P138900PC00

[0002] Title: COMBINATIONS OF CATIONIC ALPHA-HELICAL ANTIMICROBIAL PEPTIDE AND D-ARGININE OR D-LYSINE FOR USEAGAINST BACTERIAL INFECTIONS

[0003] Field of the invention

[0004] The invention relates to the field of medical and veterinary science. More specifically the invention relates to the field of antimicrobial peptides and to counteracting bacterial infections.

[0005] Background of the invention

[0006] Antimicrobial peptides are naturally occuring peptides of the innate immune system of (in)vertrebrates. Their main function is to kill bacteria upon infection and as such are an essential component of the defence system of organisms. These small cationic proteins have broad spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria. Most AMPs act by binding to the negatively charged bacterial membrane leading to permeabilization of this membrane and subsequent leakage of the cytosolic content, eventually killing the bacterium. In addition to their antimicrobial activity, AMPs are important effector molecules in inflammation, immune activation, and wound healing. AMPs are diverse in sequence and secondary structure, but share some common properties. They are usually cationic, amphipathic and exert their microbicidal effect by compromising the bacterial membrane integrity. Interaction of AMPs with the anionic membrane surface of the target bacteria leads to membrane permeabilization, lysis and death.

[0007] Conventional antibiotics kill bacteria by binding to targets such as an epitope on the cell wall, bacterial proteins or targets in DNA or RNA synthesis. The overuse and misuse of antibiotics in veterinary medicine have led to the emergence of resistant bacterial strains, such as multidrug-resistant Staphylococcus aureus. This resistance not only diminishes the effectiveness of standard treatments but also poses risks to food safety and public health through potential zoonotic transmission. Antibiotic resistance is a growing concern in the treatment of e.g. mastitis caused by intramammary infections in dairy cows, canine urinary tract infections, Salmonella and Campylobacter infections in poultry and S. suis and E. coli infections in pigs, complicating management strategies and threatening animal welfare. A major advantage of AMPs over conventional antibiotics is that resistance does not readily develop. One reason for this is that they do not target single defined molecular structures (epitopes) like conventional antibiotics, but acton the cell membrane killing microorganisms. AMPs are therefore seen as a potential alternative for conventional antibiotics.

[0008] A disadvantage of the use of AMPs is that peptides are relatively expensive molecules compared to conventional antibiotics. In addition, AMPs have a relatively high undesired cytotoxicity and / or hemolytic activity in therapeutically effective concentrations. Hence, there remain a need in the art for improved, in particular effective, save and cost-effective, treatment of bacterial infections.

[0009] Summary of the invention

[0010] It is an object of the present invention to provide treatment options for bacterial infections that provide effective therapy that overcomes one or more of the disadvantages described herein above.

[0011] The invention therefore provides a combination of an antimicrobial peptide and a positively charged D-amino acid for use in the treatment or prevention of a bacterial infection in a subject.

[0012] In a further aspect, the invention provides a method for the treatment or prevention of a bacterial infection in a subject, comprising administering to the subject a combination of an antimicrobial peptide and a positively charged D-amino acid.

[0013] In a further aspect, the invention provides a composition comprising an antimicrobial peptide and a positively charged D-amino acid for use in the treatment or prevention of a bacterial infection in a subject.

[0014] In a further aspect, the invention provides a pharmaceutical composition comprising an antimicrobial peptide, a positively charged D-amino acid and a pharmaceutically acceptable carrier and / or excipient.

[0015] In a further aspect, the invention provides a kit of parts comprising i) a pharmaceutical composition comprising an antimicrobial peptide and a pharmaceutically acceptable carrier and / or excipient, and ii) a pharmaceutical composition comprising a positively charged D-amino acid and a pharmaceutically acceptable carrier and / or excipient.

[0016] Detailed description

[0017] As used herein, "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, the verb “to consist” may be replaced by “to consist essentially of’ meaning that a compound or adjunct compound as defined herein may comprise additional component(s) than the ones specificallyidentified, said additional component(s) not altering the unique characteristic of the invention.

[0018] The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0019] The word “approximately” or “about” when used in association with a numerical value (e.g. approximately 10, about 10) preferably means that the value may be the given value (e.g. 10), plus or minus 5% of the value (e.g. 10, plus or minus 5%), preferably plus or minus 1% of the value.

[0020] The use of the alternative (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives.

[0021] The term "peptide" as used herein means a chain of amino acids coupled by a peptide bond. A peptide, in particular antimicrobial peptide as defined herein, can be linear, i.e. wherein the first and last amino acids of the sequence have a free NH2- or COOH- group respectively, or are N-terminally (e.g. acetylation) and / or C-terminally (e.g. amidation) modified, or can be cyclic.

[0022] In amino acid sequences or variants thereof as defined herein amino acids are denoted by single-letter symbols. These single-letter symbols and three-letter symbols are well known to the person skilled in the art and have the following meaning: A (Ala) is alanine, C (Cys) is cysteine, D (Asp) is aspartic acid, E (Glu) is glutamic acid, F (Phe) is phenylalanine, G (Gly) is glycine, H (His) is histidine, I (Ile) is isoleucine, K (Lys) is lysine, L (Leu) is leucine, M (Met) is methionine, N (Asn) is asparagine, P (Pro) is proline, Q (Gin) is glutamine, R (Arg) is arginine, S (Ser) is serine, T (Thr) is threonine, V (Vai) is valine, W (Trp) is tryptophan, Y (Tyr) is tyrosine. As used herein, upper case single-letter symbols for amino acids indicate L-amino acids and lower case single-letter symbols for amino acids indicate D-amino acids. As used herein, a “positively charged amino acid” refers to an amino acid that has a positive charge at physiological pH, i.e. at a pH of 7.3-7.4.

[0023] The percentage of identity of an amino acid sequence, or the term “% sequence identity”, is defined herein as the percentage of residues of the full length of an amino acid sequence that is identical with the residues in a reference amino acid sequence after aligning the two sequences. Methods and computer programs for the alignment are well known in the art, for example " Align 2". Programs for determining sequence identity are also well known in the art, for example, the BESTFIT, FASTA and GAP programs. These programs are readily utilized with the default parameters recommended by the manufacturer.

[0024] Examples of conservative amino acid substitutions, unlikely to affect antibacterial activity, include the following: alanine for serine, valine for isoleucine,aspartate for glutamate, threonine for serine, alanine for glycine, alanine for threonine, serine for asparagine, alanine for valine, serine for glycine, tyrosine for phenylalanine, alanine for proline, lysine for arginine, aspartate for asparagine, leucine for isoleucine, leucine for valine, alanine for glutamate, aspartate for glycine, and vice versa. Preferably, a conservative substitution is an exchange of one amino acid within a group for another amino acid within the same group, whereby the groups are the following: (1) alanine, valine, leucine, isoleucine, methionine, and phenylalanine: (2) histidine, arginine, lysine, glutamine, and asparagine; (3) aspartate and glutamate; (4) serine, threonine, alanine, tyrosine, phenylalanine, tryptophan, and cysteine; and (5) glycine, proline, and alanine.

[0025] The present inventors discovered that the antibacterial activity of certain D-amino acids and certain antimicrobial peptides is synergistically increased when they are combined. It was shown that in culture medium as well as under physiological conditions, i.e. urine and raw cow milk, cationic antimicrobial peptides that exert their activity by increasing bacterial membrane permeability and positively charged D-amino acids exhibit a strong synergistic effect against multiple bacterial species that cause urinary tract infections or mastitis.

[0026] Remarkably, when combined, the antimicrobial peptides and positively charged D-amino acids attain a bactericidal effect of up to 100% in concentrations wherein these agents do not have any bactericidal effect as monotherapy.

[0027] In a first aspect, the invention therefore provides a combination of an antimicrobial peptide and a positively charged D-amino acid for use in the treatment or prevention of a bacterial infection in a subject. Also provided is a method for the treatment or prevention of a bacterial infection in a subject, comprising administering to the subject a combination of an antimicrobial peptide and a positively charged D-amino acid.

[0028] In a further aspect, the invention provides a pharmaceutical composition comprising an antimicrobial peptide, a positively charged D-amino acid and a pharmaceutically acceptable carrier and / or excipient. In some embodiments, the pharmaceutical composition is a veterinary composition. In some embodiments, the pharmaceutical compositions are for human use.

[0029] In a further aspect, the invention provides a kit of parts comprising a pharmaceutical composition comprising an antimicrobial peptide and a pharmaceutically acceptable carrier and / or excipient, and a pharmaceutical composition comprising a positively charged D-amino acid and a pharmaceutically acceptable carrier and / or excipient.

[0030] The antimicrobial peptide and the positively charged D-amino acid are herein also referred to as “the agents” or “the active agents”.

[0031] In some embodiments, the method or use according to the invention is for treatment or prevention of a bacterial infection in a subject in need thereof. As used herein, the term “subject” encompasses humans and animals. Preferably the subject is an animal, more preferably a mammal or avian subject. In preferred embodiments, the subject is a livestock animal, such as a swine (pig), horse, donkey, bison, deer, alpaca, llama, sheep, lamb, goat, bovine including dairy and beef cattle (e.g. cow, yak, zebu or water buffalo), horse, farmed fish (e.g. salmon), and birds (e.g. chickens, ducks and goose), or a companion animal, such as dog, cat, rabbit, a rodent, e.g., guinea pig, hamster, gerbil, chinchilla or squirrel, fish, and birds. In some preferred embodiments, the subject is a dairy animal, in particular a goat, sheep, cow, yak, zebu or water buffalo.

[0032] The subject in need thereof is preferably a subject suffering from the bacterial infection or at risk of suffering from the bacterial infection. A subject at risk of suffering from infection is for instance a subject, preferably an animal as defined herein, that is in contact with subjects suffering from the bacterial infection, e.g. if they are kept in the same space, land, stable, house or farm.

[0033] D-amino acids (dextrorotary amino acids) are the enantiomeric counterparts of L-amino acids (levorotary amino acids). D-amino acids have been long believed to play only a minor role in bacteria as part of the peptidoglycan layer of the bacterial cell wall. Nowadays it is known that they are also found in plants, animals and humans where they play a major role in several physiological processes and functions, such as signaling molecules in neurotransmission and hormone secretion. In 2009, it was revealed that several bacteria produce D-amino acids that are excreted in millimolar concentrations in their environment (Lam et al., 2009). Several (potential) regulatory functions have now been assigned to secreted D-amino acids including the prevention of growth of competing bacteria in polymicrobial communities. For example, to compete, D-Arginine is used by V. cholerae as a toxic extracellular effector, influencing the growth and morphogenesis of competing microbes (Alvarez et al., 2018).

[0034] A “positively charged D-amino acid” as used herein refers to a D-amino acid that carries a positive charge at physiological pH, i.e. at a pH of 7.3-7.4, and includes the D-amino acids D-arginine (D-Arg), D-lysine (D-Lys) and D-histidine (D-His). In preferred embodiments, the positively charged D-amino acid is D-Arg and / or D-Lys. In preferred embodiment the positively charged D-amino acids isisolated D-Arg and / or D-Lys. As demonstrated in the Examples herein soluble D-Arg and D-Lys are able to boost the efficacy of antimicrobial peptides when administered in a sub-lethal dose.

[0035] Antimicrobial peptides can be classified into different categories. The antimicrobial peptide in a combination or composition of the invention or used in accordance with the invention is preferably a cationic antimicrobial peptide. These peptides carry a net positive charge in neutral environments, typically provided by arginine or lysine residues. Additionally cationic antimicrobial peptide typically contain a large fraction of hydrophobic amino acid residues. Hence, in preferred embodiments the antimicrobial peptide is a cationic antimicrobial peptides comprising one or more arginine or lysine residues. Cationic antimicrobial peptides include cationic α-helical AMPs, cationic ß-sheet AMPs and cationic AMPs that lack a regular secondary structure. In a preferred embodiment, the cationic AMP is an α-helical AMP.

[0036] In further preferred embodiments, the cationic antimicrobial peptide exerts antibacterial activity by interacting with negatively charged bacterial membrane thereby increasing membrane permeability. These cationic antimicrobial peptides are also referred to as pore-forming antimicrobial peptides. Hence, in preferred embodiments, the cationic antimicrobial peptide is a pore-forming cationic antimicrobial peptide. As used herein “pore formation” refers to the formation of leaky pores in the bacterial cytoplasmic membrane and / or outer membrane of bacteria.

[0037] These cationic AMPs exert antibacterial activity by interacting with negatively charged bacterial membrane to increase membrane permeability and lead to cell membrane lysis and cell content release. Gram-positive bacteria contain a cytoplasmic lipid membrane and a thick multilayered peptidoglycan layer as cell wall. In Gram-positive bacteria the negative charge of the cell wall is provided by the presence of teichoic acids linked to either the peptidoglycan, or to the underlying cytoplasmic membrane. Gram-negative bacteria have a thin, typically monolayered peptidoglycan covered by an outer cell membrane. The outer cell membrane contains phospholipids and lipopolysaccharides which provide a net negative charge to the Gram-negative bacteria.

[0038] Many natural and synthetic cationic antimicrobial peptides that exerts their activity by interacting with negatively charged bacterial membrane and increasing membrane permeability are known in the art, as well as method to determine whether an antimicrobial peptide has this mechanism of action. For instance, model membrane systems such as lipid vesicles can be used to determine the modeof action of AMPs. E.g. the ability of a peptide to cause leakage of a cellular membrane may be determined for example by measuring the leakage of fluorescent or colorimetric dyes from artificially formed model membranes, such as lipid or phospholipid vesicles. Detailed methods are described in Schafer and Wenzel (Front Cell Infect Microbiol. 2020 Oct 19; 10:540898.) and Omardien et al. (Front Cell Dev Biol. 2016 Oct 14;4:111), which are incorporated herein by reference.

[0039] Examples of cationic antimicrobial peptides include cathelicidins, cecropins, defensins, protegrins and histatins. Hence, in preferred embodiments, the antimicrobial peptide is selected from the group consisting of cathelicidins, cecropins, defensins, protegrins and histatins.

[0040] In some preferred embodiments, the cationic antimicrobial peptide is a cathelicidin. Cathelicidins are antimicrobial peptides found in humans and other animals, including cattle, horses, pigs, sheep, goats, chickens, rabbits and in some fish. As used herein the term “cathelicidins” includes antimicrobial derivatives of cathelicidins, e.g. truncated peptides and peptides comprising one or more amino acid mutations that have retained antimicrobial activity. In some preferred embodiments the cathelicidin is selected from the group consisting of EE-37 (human cathelicidin), CAMP cathelicidin antimicrobial peptide, RL-37 (rhesus monkey cathelicidin), CRAMP (mCRAMP, mouse cathelicidin), CRAMP (rCRAMP, rat cathelicidin), CAP- 11 (guinea pig cathelici din), CAP- 18, P-15R, P-15 (rabbit cathelicidins), eCATH-1, eCATH-2 and eCATH-3 (horse cathelicidin), PMAP-37, PMAP-36, PMAP-23, PR-39, PF-1, PF-2, Protegrin-1 (PG-1), PG-2, PG-3, PG-4, PG-5 (porcine cathelicidins), BMAP-27, BMAP-28, BMAP-34, Bac-1, Bac-5 and Bac-7, indolicidin, and bactenecin-1 (bovine cathelicidins), cathelici din-4 and myeloid cathelicidin (buffalo cathelicidins), BAC-5, BAC-7.5, MAP-34A, MAP-34B, MAP-28, ChBac-3.4 (goat cathelicidins), SMAP-29, SMAP-34, Bac-5, Bac-6, Bac-7, Bac-7.5, Bac-11, CATHL-1A, CATHL-1B, SMAP-29, MAP-34 (sheep cathelicidins), CATH-1, CATH-2 (CMAP-27), CATH-3 and CATH-B1 (chicken cathelicidins), snake venom cathelicidins, such as AB-CATH (prong-snouted blind snake; Anilos bitubercalatus cathelici din), OH-CATH (king cobra; Ophiophagus Hannah cathelici din), NA-CATH (Chinese cobra; Naja atra cathelicidin), Cathelicidin-BF (banded krait; Bungarus fasciatus cathelicidin), Pt_CRAMPl and Pt_CRAMP2 (Eastern-brown-snake; Pseudonaja textilis cathelicidins), SA-CATH (Chinese snake; Sinonatrix annularis cathelicidin), CATHPbl (Burmese python; Python bivittatus cathelicidin), and Hc-CATH (Blue-banded sea snake; Hydrophis cyanocinctus cathelicidin), asCATH-1 and asCATH-2, rtCATH-1 and rtCATH-2 (fish cathelicidins), and antimicrobially active derivatives thereof.

[0041] In a preferred embodiment, the cathelicidin is selected from the group consisting of chicken cathelicidins (CATH-1, CATH-2, CATH-3 and CATH-B1) and pig cathelicidins (PMAP-37, PMAP-36, PMAP-23, PG-1, PG-2, PG-3, PG-4, PG-5, PR-39, PF-1, PF-2) and antimicrobially active derivatives thereof.

[0042] In a further preferred embodiment, the antimicrobial peptide is selected from PMAP-36, CATH-2, chicken CATH-1, chicken CATH-3, FK-18, OH-CATH, AB-CATH, DCATH-2, CATH-2(4-21) and DCATH2(4-21).

[0043] In further preferred embodiments, the antimicrobial peptide is CATH-2 (also referred to as CMAP-27), PMAP-36, CRAMP (cathelicidin-related antimicrobial peptide), LL-37 or PR-39 or an antimicrobially active derivatives thereof.

[0044] CATH-2 is also referred to as CMAP-27. The 27 amino acid sequence of this C-terminal peptide, called CMAP-27 or CATH-2, is RFGRFLRKIRRFRPKVTITIQGSARFG.

[0045] DCATH-2 consists of the sequence of CATH-2 wherein all amino acids are D-amino acids. DCATH-2 has the sequence rfgrflrkirrfrpkvtitiqgsarfg.

[0046] Porcine myeloid PMAP-36 is a highly cationic, 36-amino acid long cathelici din. The N-terminal region is characterized by several charged residues and is organized as an u-helical structure interrupted by three proline residues. The 36 amino acid sequence of PMAP-36 is GRFRRLRKKTRKRLKKIGKVLKWIPPIVGSIPLGCG.

[0047] LL-37 has the sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES.

[0048] CRAMP has the sequence GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ.

[0049] PR-39 has the sequence RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP.

[0050] FK-18 has the sequence FCKLFKRVYRFYKHWAHK.

[0051] AB-CATH has the sequence KRFKKFFRKVKKGVHRYFKKNKFYIAATIPYYG.

[0052] OH-CATH has the sequence

[0053] KRFKKFFKKLKNSVKKRAKKFFKKPRVIGVSIPF.

[0054] Chicken CATH-1 has the sequence RVKRVWPLVIRTVIAGYNLYRAIKKK.

[0055] Chicken CATH-3 has the sequence RVKRFWPLVPVAINTVAAGINLYKAIRRK.

[0056] CATH-2(4-21) has the sequence RFLRKIRRFRPKVTITIQ

[0057] DCATH2(4-21) has the sequence rflrkirrfrpkvtitiq.

[0058] Cecropins (also referred to as Cecs) are a class of insect antimicrobial peptides first isolated from the hemolymph of the cecropia moth (Hyalophora cecropid). In addition to permeabilization of the bacterial cell membrane, they inhibit proline uptake. Preferred, but nondimiting, examples of Cecropins are Cecropin (Cec) A, Cec B, Papiliocin, Cec Pl, Oxysterlin 1, Oxysterlin 2, Oxysterlin 13, Ced, Sarcotoxin Pd, SibaCec, AngCec A, AeaeCec 1, AeaeCec 2–4, AeaeCec 5, Cec Al, Cec B2, Cec C, Cec D, Cec E, CecTYl, CLP1, Mdc, Cec, Stomoxyn, Sarcotoxin I, Sarcotoxin A, Sarcotoxin B, Sarcotoxin C, Lser Cecs 1-6, LSerStomox 1, 2, Spodopsin la, Spodopsin lb, AcCec D, Hinnavin I, Hinnavin II, DANI, DAN2 and derivatives thereof.

[0059] Defensins are a large family of host defense peptides with a ß-sheet core structure stabilized by three conserved intramolecular disulfide bonds, expressed mainly in neutrophils and epithelial cells. Defensins are classified in different classes, including α-defensins, ß-defensins, and θ-defensins. Non-limiting examples of α-defensins include HNP 1–4 (human neutrophils), HD 5 and 6 (human Paneth cells), RabNP-1 (rabbit granulocytes and alveolar macrophages), and RatNP-1 (rat neutrophils). Non-limiting examples of ß-defensins include Gal-2 (gallinacin-2, chicken granulocytes), TAP (tracheal antimicrobial peptide, bovine respiratory tract epithelia), BNBD-12 (bovine granulocytes), and hBD-1, -2, and -3 (human epithelial cells).

[0060] Histatins are a histidine-rich family of cationic antimicrobial peptides produced by parotid and salivary duct cells of man and some higher primates. The main members of this family are histatin 1, histatin 3 and histatin 5, while other members of this family are typically derived from by proteolytic cleavage thereof.

[0061] Antimicrobial peptide as defined herein, including cathelicidins, in particular CATH-2, PMAP-36, LL-37, CRAMP and PR-39, can be linear or cyclic. In preferred embodiments, the antimicrobial peptide, in particular cathelicidin, is a linear peptide, preferably a linear α-helical peptide, more preferably a cationic, linear, α-helical peptide. In addition, these peptides can be N-terminally (e.g. acetylation) and / or C-terminally (e.g. amidation) modified.

[0062] Derivatives of an antimicrobial peptide as used herein refer to a variant of the antimicrobial peptide that contains at least part of the sequence of the peptide, such as a truncated and / or mutated variant, and that has retained antimicrobial, in particular antibacterial, activity. For instance, derivatives of CATH-2, PMAP-36,LL-37, CRAMP and PR-39 include C-terminally and / or N-terminally truncated derivatives, D-amino acid derivatives (e.g. DCATH-2), C-terminally or N-terminally truncated D-amino acid derivatives, cyclic derivatives and inverso and retroinverso derivatives. In preferred embodiments, a derivative of an antimicrobial peptide is a C-terminally and / or N-terminally truncated derivative, a D-amino acid derivative, or a C-terminally or N-terminally truncated D-amino acid derivative of said antimicrobial peptide. Preferred derivatives of CATH-2 include CATH-2(l-26) (RFGRFLRKIRRFRPKVTITIQGSARF), CATH-2(1-21) (RFGRFLRKIRRFRPKVTITIQ), CATH-2(4-21) (RFLRKIRRFRPKVTITIQ), CATH-2(7-21) (RKIRRFRPKVTITIQ), CATH-2(1-15) (RFGRFLRKIRRFRPK), DCATH-2 (rfgrflrkirrfrpkvtitiqgsarfg), DCATH-2(l-26) (rfgrflrkirrfrpkvtitiqgsarf), DCATH-2(1-21) (rfgrflrkirrfrpkvtitiq), DCATH-2(4-21) (rflrkirrfrpkvtitiq), DCATH-2(7-21) (rkirrfrpkvtitiq), and DCATH-2(1-15) (rfgrflrkirrfrpk).

[0063] In some preferred embodiments, the antimicrobial peptide is selected from PMAP-36, CATH-2, chicken CATH-1, chicken CATH-3, OH-CATH, AB-CATH and a derivative of any thereof. Preferably the derivative is a C-terminally and / or N-terminally truncated derivative, a D-amino acid derivative, or a C-terminally or N-terminally truncated D-amino acid derivative of PMAP-36, CATH-2, chicken CATH-1, chicken CATH-3, OH-CATH, or AB-CATH.

[0064] In some preferred embodiments, the antimicrobial peptide is selected from PMAP-36, CATH-2, chicken CATH-1, chicken CATH-3, OH-CATH, AB-CATH, DCATH-2, CATH-2(4-21) and DCATH2(4-21).

[0065] In some preferred embodiments, the cationic antimicrobial peptide is CATH-2 or PMAP-36.

[0066] The combination or composition of the invention typically comprises a single cationic antimicrobial peptide. However, such combination or composition may also comprise two or more cationic antimicrobial peptides.

[0067] An antimicrobial peptide used in accordance with the invention typically have a length of, or consist of, up to 60 amino acids. In preferred embodiments, the antimicrobial peptide has a length of, or consist of, 10-60 amino acids, more preferably 10-50 amino acids, more preferably 10-40 amino acids, more preferably 15-40 amino acids. In some preferred embodiments, the antimicrobial peptide is a cationic u-helical antimicrobial peptide with a length of 10-40, more preferably 15-40 amino acids, preferably a cathelicidin with a length of 10-40, more preferably 15-40 amino acids.

[0068] The antimicrobial peptide used in accordance with the invention can be commercially available, can be produced synthetically or, where applicable, recombinantly by conventional methods. Suitable methods are well known in the art and for instance described in van Dijk, A., et al., Identification of chicken cathelicidin-2 core elements involved in antibacterial and immunomodulatory activities (Mol Immunol, 2009. 46(13): p. 2465-73) and van Dijk, A., et al., Immunomodulatory and Anti-Inflammatory Activities of Chicken Cathelicidin-2 Derived Peptides (PLoS One, 2016. 11(2): p. e0147919), which are incorporated herein by reference. The antimicrobial peptides are prepared conventionally by known chemical synthesis techniques, such as, for instance, are disclosed by Merrifield (J. Am. Chem. Soc. (1963) 85:2149-2154). They may be isolated from the reaction mixture by chromatographic methods, such as reverse-phase HPLC.

[0069] Alternatively, an antimicrobial peptide used in accordance with the invention may be produced by recombinant DNA techniques by cloning and expressing within a host micro-organism or cell a DNA fragment carrying a nucleic acid sequence encoding one of the above-described peptides. Nucleic acid coding sequences can be prepared synthetically, or may be derived from existing nucleic acid sequences. These nucleic acid sequences may then be cloned in a suitable expression vector and transformed or transfected into a suitable host cell, such as

[0070] E. coli, Bacillus, Lactobacillus, Streptomyces, mammalian cells (such as CHO, HEK or COS-1 cells), yeasts (e.g. Saccharomyces, Schizophyllum), insect cells or viral expression systems, such as baculovirus systems, or plant cells. A person skilled in the art will have knowledge of the techniques of constructing the nucleic acid sequences and providing means to enable their expression. Subsequently, the antimicrobial peptide can be isolated from the culture of the host cells. This can be achieved by common protein purification and isolation techniques, which are available in the art. Such techniques may e.g. involve immunoadsorption or chromatography. It is also possible to provide the peptides with a tag (such as a histidine tag) during synthesis, which allows for a rapid binding and purification, after which the tag is enzymatically removed to obtain the active peptide.

[0071] Alternatively, the antimicrobial peptide can be produced in cell-free systems, such as the Expressway™ cell-free system of Invitrogen.

[0072] Some more comprehensive summaries of methods which can be applied in the preparation of peptides, i.e. including antimicrobial peptides, are described in: W.

[0073] F. Anderson, Nature 392 Supp., 30 April 1998, p. 25-30; Pharmaceutical Biotechnology, Ed. D. J. A. Crommelin and R. D. Sindelar, Harwood Academic Publishers, 1997, p. 53-70, 167-180, 123-152, 8-20; Protein Synthesis: Methods and Protocols, Ed. R. Martin, Humana Press, 1998, p. 1-442; Solid- Phase Peptide

[0074] Synthesis, Ed. G. B. Fields, Academic Press, 1997, p. 1-780; Amino Acid and Peptide Synthesis, Oxford University Press, 1997, p. 1-89.

[0075] Reference to a combination of an antimicrobial peptide as defined herein and a positively charged D-amino acid as defined herein indicates that the bacterial infection is treated or prevented using both the antimicrobial peptide and the positively charged D-amino acid as active ingredients.

[0076] Both agents can be administered in a single pharmaceutical composition. Hence, in some preferred embodiments a combination of an antimicrobial peptide and a positively charged D-amino acid is a pharmaceutical composition comprising both the antimicrobial peptide and the positively charged D-amino acid. Further provided is a pharmaceutical composition comprising an antimicrobial peptide, and a positively charged D-amino acid.

[0077] Alternatively, the antimicrobial peptide and positively charged D-amino acid are present in separate pharmaceutical compositions. Hence, in some preferred embodiments, a combination of an antimicrobial peptide and a positively charged D-amino acid comprise i) a pharmaceutical composition comprising the antimicrobial peptide and ii) a pharmaceutical composition comprising the positively charged D-amino acid.

[0078] If the active agents are administered in separate pharmaceutical compositions, these compositions are preferably administered concomitantly. The term “concomitant administration” is well understood in the art, and generally refers to administration of two active substances at the same time, or almost at the same time. In the present invention this means that both of the agents are administered within the same time interval. Thus, if one of the agents is given daily, the other agent is also given daily, on the same day. If one of the agents is given weekly, the other agent is also given weekly, in the same week. If one of the agents is given monthly, the other agent is also given monthly, in the same month. It will be understood that the terms “day”, “week” and “month” do not necessarily refer to a calender day, week, or month, but to the time intervals having the respective lengths. Preferably, both of the agents are given subsequently, and more preferably they are given simultaneously. “Subsequently” as used herein indicates that the two agents or pharmaceutical compositions comprising the agents are administered within one hour, more preferably within 0.5 hour, more preferably within 15 minutes. Preferably the two agents or pharmaceutical compositions comprising the agents are administered immediately one after the other. Most preferably, the simultaneous administration is effected through one single pharmaceutical composition comprising both of the agents.

[0079] A pharmaceutical composition according to the invention or used in accordance with the invention further comprises a pharmaceutically acceptable carrier, diluent and / or excipient. By "pharmaceutically acceptable" it is meant that the carrier or excipient must be compatible with the other ingredients of the formulation and not deleterious, e.g. toxic, to the recipient thereof. In general, any pharmaceutically suitable additive which does not interfere with the function of the active compounds can be used. A pharmaceutical composition according to the invention is preferably suitable for veterinary use. Examples of suitable carriers comprise a solution, lactose, starch, cellulose derivatives and the like, or mixtures thereof. Compositions for intravenous administration or administration by injection may for example be solutions of the antimicrobial peptide and / or positively charged D-amino acid in sterile isotonic aqueous buffer. Where necessary, the compositions may include for instance solubilizing agents, stabilizing agents and / or a local anesthetic to ease the pain at the site of the injection.

[0080] In one embodiment, the methods and uses of the invention are for the treatment of existing bacterial infection. As used herein, the terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment maybe administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.

[0081] In one embodiment, the methods and uses of the invention are for prevention of bacterial infection. As used herein, the term “prevention” refers to precluding or delaying the onset of a disease or condition and / or the appearance of clinical symptoms of the disease or condition in a subject that does not yet experience clinical symptoms of the disease.

[0082] As used herein, the term “active agent” refers to a substance that has or is capable or exerting an activity in an organism, preferably in a subject as defined herein, when administered in an effective dose.

[0083] A combination of the invention has antibacterial activity. The term “antibacterial activity” as used herein refers to counteracting growth or

[0084] proliferation of at least one bacterial species and includes inhibition, reduction or prevention of growth or proliferation, as well as killing thereof.

[0085] Antibacterial activity can be measured by methods known in the art.

[0086] Examples of such methods for determining antibacterial activity of a combination of an antimicrobial peptide and a D-amino acid are detailed in the Examples herein and involve an in vitro assay for determination of antibacterial activity. In one such method colony count assays are performed in for instance culture medium or raw milk. Bacteria are grown to logarithmic phase, and the medium or raw milk is spiked with the bacteria and treated with the antimicrobial peptide and D-amino acid or e.g. a concentration range thereof. After incubation, e.g. at several timepoints, samples can be taken, plated, incubated for 24h, followed by counting of viable bacteria.

[0087] The combination according to the invention have synergistic antibacterial activity. Synergy refers to an antibacterial effect that is larger than the antibacterial effect of the sum of the antibacterial activity of the two agents when used separately. Antimicrobial synergy of a combination of compounds can for instance be determined using a checkerboard dilution assay as described in the Examples herein. Such assay can be used to determine the change in antibacterial efficacy of a combination of compounds relative to their individual activity. In such checkerboard assays, the Minimum Inhibitory Concentration (MIC) or Minimum Bactericidal Concentration (MBC) values of both compounds are determined alone at each concentration in serial dilution range, and compared with the effect of the combination. Synergy is determined by calculating the fractional inhibitory concentration index (FICI) = MIC of drug A in combination / MIC of drug A alone + MIC of drug B in combination / MIC of drug B alone. The calculated FICI is interpreted as synergistic for FICI <0.5; additive for 0.5< FICI<1; indifferent for 1< FICI <4.0, and antagonistic for FICI> 4.

[0088] As used herein the term “bacterial infection” refers to an infection caused by one or more bacterial species or strains. The infection may be present in any one or more tissues of the subject. The inventors have shown the synergistic antibacterial effect of an antimicrobial peptide and a positively charged D-amino acid for multiple Gram-positive bacteria, including bacteria that are resistant to antibiotics, such as Staphylococcus aureus, including multidrug-resistant Staphylococcus aureus, Bacillus cereus, Streptococcus uberis, Streptococcus agalactiae and Listeria monocytogenes, and for the Gram-negative bacteria Escherichia coli and Salmonella enterica serovar Enteritidis. Hence, the bacterial infection that is treated with a combination in accordance with the invention canbe an infection with Gram-positive, Gram-negative bacteria, mycoplasma or mycobacterium spp. Examples of such bacterial infections include, but are not limited to, E. coli, Agrobacterium tumefaciens, Salmonella Enteritidis, Salmonella typhimurum, Erwinia carotovora, E. herbicola, E. chrysanthemi, Klebsiella pneumoniae, Haemophilus influenzae, Francisella tularensis, Archanobacterium pyogenes, Avibacterium paragallinarum, Bacillus anthracis, Bacillus megaterium, Bacillus anthracis, Bacillus cereus, Bordetelle spp., Brachyspira spp., Brucella spp., Campylobacter spp., Clostridium botulinum, Clostridium perfringens, Clostridium septicum, Corynebacterium pyogenes, Coxiella burnetii, Enterococcus spp., Haemophilus somnus, Yersinia pestis, Listeria monocytogenes, Mannheimia haemolytica, Mycobacterium tuberculosis, Mycobacterium avium, Mycoplasma gallisepticum, Mycoplasma synoviae, Ornithobacterium rhinotracheale, Pasteurella aeruginosa, Pastuerella multocida, Pneumococcus spp. Pseudomonas aeruginosa, Riemerella anatipestifer, Salmonella spp., Streptococcus uberis, Streptococcus agalactiae, Streptococcus spp., Staphylococcus aureus, Staphylococcus pyrogenes, Truperella pygoenes, Vibria cholerae, Micrococcus luteus, Moraxella, Neisseria ghonnorhoea, Aerobacter, Borellia.

[0089] In preferred embodiments, the infection is an infection with a Gram-positive or Gram-negative bacterium. In preferred embodiments, the infection is an infection with a Gram-positive bacterium. In further preferred embodiments, the infection is an infection with a bacterium selected from the group consisting of Escherichia coli, Staphylococcus aureus, including multi- drug resistant, Streptococcus uberis, Streptococcus agalactiae, Streptococcus pneumoniae, Pseudomonas aeruginosa, Heamophilus influenzae, Klebsiella pneumonaie, Proteus mirabilis and any combination thereof. In further preferred embodiments, the infection is an infection with a bacterium selected from the group consisting of Escherichia coli, Staphylococcus aureus, including multi- drug resistant, Streptococcus uberis, Streptococcus agalactiae, Bacillus cereus, Listeria monocytogenes, and any combination thereof.

[0090] In further preferred embodiments, the infection is an infection with a bacterium selected from the group consisting of Escherichia coli, Staphylococcus aureus, Streptococcus uberis, Streptococcus agalactiae, and any combination thereof.

[0091] In further preferred embodiments, the infection is an infection with a bacterium selected from the group consisting of Staphylococcus aureus, Streptococcus uberis, Streptococcus agalactiae, and any combination thereof.

[0092] Moreover bacterial infections in any type of tissue can be treated with a combination of an antimicrobial peptide and a positively charged D-amino acid according to the present invention, including, but not limited to, an intramammary infection, preferably mastitis, urinary tract infection, dermatitis, eye infection, ear infection, venereal infection, and respiratory tract infection.

[0093] In some preferred embodiments, the bacterial infection is an intramammary infection, preferably mastitis. In further preferred embodiments, the bacterial infection is an intramammary infection, preferably mastitis, and the subject is a bovine, in particular a dairy cow, a goat, a sheep or a horse. Mastitis is an inflammatory condition of the udder tissue, commonly caused by bacterial infection, in particular an intramammary infection. Mastitis is one of the most significant diseases in dairy cows, leading to milk production loss and economic impact on dairy farms. In the Netherlands the financial loses for the dairy industry are on average €240 / lactating cow per year. The disease can be classified into clinical and subclinical forms, with clinical mastitis presenting visible signs such as swelling, redness, and abnormal milk, while subclinical mastitis often remains undetected but can lead to substantial losses in milk yield and quality. Two of the main pathogens responsible for bovine mastitis are the Gram-positive Staphylococcus aureus and the Gram-negative Escherichia coli. Hence, in some preferred embodiments, the bacterial infection is an intramammary infection, preferably mastitis, caused by Staphylococcus aureus, including multi-drug resistant S. aureus, and / or Escherichia coli. Other bacteria causing intramammary infections responsible for mastitis include non-aureus staphylococci and mammaliicocci (including Staphylococcus chromogenes, Staphylococcus heamolyticus, Staphylococcus epidermidis, Staphylococcus simulans, Staphylococcus equorum, Staphylococcus warneri, Staphylococcus cohnii, Staphylococcus hominis, Staphylococcus capitis, Staphylococcus xylosis, Staphylococcus lugdunensis, Staphylococcus caprae, Mammaliicoccus sciuri, Mammaliicoccus fleurettii, Mammaliicoccus lentus and other Staphylococcus spp. and Mammaliicoccus spp.), Streptococcus uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus canis, Trueperella pyogenes, Corynebacterium bovis and other spp., Klebsiella oxytoca, Klebsiella pneumoniae and other spp., Mycoplasma bovis and other spp., Pseudomonas aeruginosa and other spp., Serratia marcescens and other spp., Mannheimia haemolytica, Enterococcus saccharolyticus, Enterococcus faecium, Enterococcus cecorum and other spp., Bacillus cereus and other spp., and Listeria monocytogenes. Hence, in some preferred embodiments, the bacterial infection is an intramammary infection caused by Staphylococcus aureus, including multi-drug resistant S. aureus, non-aureus staphylococci and mammaliicocci (including Staphylococcus chromogenes, Staphylococcus heamolyticus, Staphylococcus epidermidis, Staphylococcus simulans, Staphylococcus equorum, Staphylococcus warneri, Staphylococcus cohnii, Staphylococcus hominis, Staphylococcus capitis, Staphylococcus xylosis, Staphylococcus lugdunensis, Staphylococcus caprae, Mammaliicoccus sciuri, Mammaliicoccus fleurettii, Mammaliicoccus lentus and other Staphylococcus spp. and Mammaliicoccus spp.), Streptococcus uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus canis, Trueperella pyogenes, Corynebacterium bovis and other Corynebacterium spp., Klebsiella oxytoca, Klebsiella pneumoniae and other Klebsiella spp., Mycoplasma bovis and other spp., Pseudomonas aeruginosa and other Pseudomonas spp., Serratia marcescens and other Serratia spp., Mannheimia haemolytica, Enterococcus saccharolyticus, Enterococcus faecium, Enterococcus cecorum and other Enterococcus spp., Bacillus cereus and other Bacillus spp., Listeria monocytogenes and / or E. coli.

[0094] In some preferred embodiments, the bacterial infection is an intramammary infection, preferably mastitis, and the infection is caused by a bacterium selected from the group consisting of Staphylococcus aureus, Bacillus cereus, Streptococcus uberis, Streptococcus agalactiae, Listeria monocytogenes, Salmonella enteritidis, Pseudomonas aeruginosa, Escherichia coli and any combination thereof

[0095] In some preferred embodiments, the bacterial infection is a urinary tract infection, preferably a urinary tract infection caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis or Staphylococcus saprophyticus in both humans and animals.

[0096] In some preferred embodiments, the bacterial infection is an eye infection, preferably an eye infection caused by Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Neisseria gonorrhoeae or Neisseria meningitidis, in particular in humans, and by Staphylococcus spp. Pseudomonas aeruginosa, Enterococcus spp, Moraxella bovis or Corynebacterium spp, in particular in animals.

[0097] In some preferred embodiments, the bacterial infection is an ear infection, preferably an ear infection caused by Streptococcus pneumoniae or Haemophilus influenzae, in particular in humans and by Staphylococcus spp. Pseudomonas aeruginosa, Proteus spp, Klebsiella spp. Enterococcus spp, Moraxella bovis or Corynebacterium spp, in particular in animals.

[0098] In some preferred embodiments, the bacterial infection is a venereal infection, in particular brucellosis, syphilis and campylobacteriosis. Brucellosis is a bacterial disease caused by various Brucella species, which mainly infect cattle, swine, goats, sheep and dogs.

[0099] In some preferred embodiments, the bacterial infection is a respiratory tract infection, such as pneumonia, laryngitis, tracheitis, and bronchitis.

[0100] In the methods and uses of the invention, the antimicrobial peptide and positively charged D-amino acid are preferably administered parenterally. The term “parenteral administration” is is well understood in the art, and generally refers to all routes of administration other than through the gastro-intestinal tract, including but not limited to intramuscular, intravenous, subcutaneous, transdermal, transmucosal, or inhalational administration. In further preferred embodiments, administration is local administration. As used herein, local administration refers to administration of the combination of an AMP as defined herein and a positively charged D-amino acid to the site of the infection.

[0101] In some preferred embodiments, the bacterial infection is mastitis and the antimicrobial peptide and positively charged D-amino acid are administered intramammary, e.g. via intramammary injection or infusion. In some preferred embodiments, the bacterial infection is mastitis, the subject is selected from the group consisting of a bovine, in particular a dairy cow, a goat, a sheep or a horse. Intramammary administration can be achieved via injection or infusion into the infected mammary gland or glands. E.g. in the case of a dairy cow, the combination according to the invention can be administered to one or more infected quarters of the udder. Treatment of bacterial mastitis with the combination or composition of the present invention is more effective as compared to veterinary compositions comprising an AMP or positively charged D-amino acid as the sole therapeutic agent, as is demonstrated in the Examples showing synergistic bactericidal effects of the combination in raw milk.

[0102] In some preferred embodiments, the bacterial infection is urinary tract infection and the antimicrobial peptide and positively charged D-amino acid are administered to the urinary bladder. Local administration to the bladder can e.g. be achieved by cystocentesis or by urethral catheterization. Cystocentesis is a veterinary procedure in which a needle is inserted into the urinary bladder of an animal through the abdominal wall. Therapeutic cystocentesis may be employed to administer the combination according to the invention into the bladder.

[0103] In some preferred embodiments, the bacterial infection is an eye infection and the antimicrobial peptide and positively charged D-amino acid are administered to the eye. For instance, topical administration by e.g. eyedrops can be applied, as well as subconjunctival, retrobulbar, intracameral and intravitreal administration by e.g. injection or infusion.

[0104] In some preferred embodiments, the bacterial infection is an ear infection and localized treatment with the antimicrobial peptide and positively charged D-amino acid includes topical administration by ear drops, transtympanic administration and administration via the Eustachian tube.

[0105] In some preferred embodiments, the bacterial infection is a venereal infection and the antimicrobial peptide and positively charged D-amino acid are administered via lavage or ointment.

[0106] In some preferred embodiments, the bacterial infection is a respiratory tract infection and the antimicrobial peptide and positively charged D-amino acid are administered via puff or inhalers.

[0107] The combination of an antimicrobial peptide and a positively charged D-amino acid is administered in an effective dose. The term “effective dose” is well understood in the art and refers to a dose range that produces the desired effect of an active agent or combination of active agents. The effective dose is often determined based on analysing the dose-response relationship specific to the agent or agents. In the context of the invention, the term “effective dose” relates to the dose of each of the active agents when used in combination.

[0108] In preferred embodiments, the antimicrobial peptide is administered in a subeffective dose based on monotherapy and the positively charged D-amino acid is administered in a sub-effective dose based on monotherapy. As used herein “subeffective dose based on monotherapy” refers to a dose that is ineffective in treatment of the bacterial infection when the agent is administered as the sole active agent. The sub-effective dose of the antimicrobial peptide and the subeffective dose of the positively charged D-amino acid have a synergistic effect upon co-administration because when administered in combination in these doses, they do have an antibacterial effect.

[0109] In some preferred embodiments, the subeffective dose based on monotherapy of the antimicrobial peptide is a dose of 40 μM or lower. Similarly, in some preferred embodiments, the subeffective dose based on monotherapy of the positively charged D-amino acid is 80 mM or lower. As demonstrated in the Examples herein, such concentrations show a synergistic effect when they are combined, see e.g. figures 10, 14, 16, 17, 18,19 and 20. As further demonstrated, concentrations of 20 μM or lower of the antimicrobial peptide and 40 mM or lower of the D-amino acid are not effective when administered as single treatment, see e.g. figures. 3, 5, 11,13 and 15. In combination an effective antibacterial treatment is obtained when used in these concentrations.

[0110] These doses refers to the dose in the volume in which the antimicrobial peptide is injected. E.g. if the bacterial infection is an intramammary infection, preferably mastitis, and the combination according to the invention is injected intramammary, the concentration of the antimicrobial peptide is the concentration in the milk in the udder after administration of the combination according to the invention. Similarly, if the bacterial infection is a urinary tract infection and the combination according to the invention is injected in the bladder, e.g. by cystocentesis or urethral catheterization, the concentration of the antimicrobial peptide is the concentration in urine in the bladder after administration of the combination according to the invention.

[0111] Hence, in a preferred embodiment, the antimicrobial peptide is administered in a concentration of 20 μM or lower and / or the positively charged D-amino acid is administered in a concentration of 40 mM or lower.

[0112] More preferably, the antimicrobial peptide is administered in a concentration of 20 μM or lower, more preferably in a concentration of 15 μM or lower, more preferably in a concentration of 10 μM or lower, more preferably in a concentration of 7.5 μM or lower, more preferably in a concentration of 5 μM or lower.

[0113] Furthermore, the positively charged D-amino acid is preferably administered in a concentration of 40 mM or lower, more preferably in concentration of 20 mM or lower, more preferably in concentration of 10 mM or lower, more preferably in concentration of 5 mM or lower, more preferably in concentration of 2.5 mM or lower.

[0114] In some preferred embodiments, the antimicrobial peptide is administered in a concentration of 1.25 μM or lower and the positively charged D-amino acid is administered in a concentration of 20 mM or lower.

[0115] In some preferred embodiments, the antimicrobial peptide is administered in a concentration of 2.5 μM or lower and the positively charged D-amino acid is administered in a concentration of 10 mM or lower.

[0116] In some preferred embodiments, the antimicrobial peptide is administered in a concentration of 5 μM or lower and the positively charged D-amino acid is administered in a concentration of 5 mM or lower.

[0117] In some preferred embodiments, the antimicrobial peptide is administered in a concentration of 10 μM or lower and the positively charged D-amino acid is administered in a concentration of 2.5 mM or lower.

[0118] In some preferred embodiments, the antimicrobial peptide is administered in a concentration of 10 μM or lower and the positively charged D-amino acid is administered in a concentration of 80 mM or lower, in particular in the treatmentof mastitis and whereby the antimicrobial peptide and positively charged D-amino acid are administered in the udder.

[0119] In some preferred embodiments, the antimicrobial peptide is administered in a concentration of 20 pM or lower and the positively charged D-amino acid is administered in a concentration of 20 mM or lower, in particular in the treatment of mastitis and whereby the antimicrobial peptide and positively charged D-amino acid are administered in the udder.

[0120] In some preferred embodiments, the antimicrobial peptide is administered in a concentration of 40 pM or lower and the positively charged D-amino acid is administered in a concentration of 10 mM or lower, in particular in the treatment of mastitis and whereby the antimicrobial peptide and positively charged D-amino acid are administered in the udder.

[0121] Features may be described herein as part of the same or separate aspects or embodiments of the present invention for the purpose of clarity and a concise description. It will be appreciated by the skilled person that the scope of the invention may include embodiments having combinations of all or some of the features described herein as part of the same or separate embodiments.

[0122] The invention will be explained in more detail in the following, non-limiting examples.

[0123] Brief description of the drawings

[0124] Figure 1: Effect of CATH-2 and D-AA on growth of S. aureus. S. aureus (OD 0.05) was incubated with 2 pM CATH-2 and 20 mM D-AA in LB at 37 °C. The average final OD600values after 12 h of three independent measurements are schematically shown in a heatmap

[0125] Figure 2: Effect of D-amino acids on growth of S. aureus. S. aureus was incubated with different concentrations of A) D-Arg, B) D-Lys and C) D-Ser at 37 °C and growth was determined by measuring OD600every 10 min. Shown are representative curves of triplicate independent experiments.

[0126] Figure 3: Antibacterial effect of D-Arginine and CATH-2 (growth curves). S. aureus was incubated with different concentrations of D-Arg as indicated and with A) 0 pM CATH-2; B) 1,25 pM CATH-2; C) 2,5 pM CATH-2 and D) 5 pM CATH-2 at 37 °C and growth was determined by measuring OD600every 10 min. Shown are representative curves of triplicate independent experiments.: Antibacterial effect of D-Arginine and CATH-2 (viability). CATH-2 was incubated for 3 h with different concentrations of D-Arg.

[0127] Subsequently, bacterial viability was determined by plating out on TSA plates. Shown are the average + StDev of 3 independent experiments.

[0128] Figure 5: Antibacterial effect of D-Arginine and CATH-2 on E. coli (growth curves). E. coli was incubated with different concentrations of D-Arg as indicated and with A) 0 pM CATH-2; B) 1,25 pM CATH-2; C) 2,5 pM CATH-2 and D) 5 pM CATH-2 at 37 °C and growth was determined by measuring OD600every 10 min. Shown are representative curves of triplicate independent experiments.

[0129] Figure 6: Antibacterial effect of D-Arginine and CATH-2 on S. uberis.

[0130] S. uberis was incubated with different concentrations of D-Arg as indicated and with A) 0 pM CATH-2; B) 1,25 pM CATH-2; C) 2,5 pM CATH-2 and D) 5 pM CATH-2 at 37 °C and growth was determined by measuring OD600every 10 min. Shown are representative curves of triplicate independent experiments.

[0131] Figure 7: Antibacterial effect of D-Arginine and CATH-2 on S. agalactidiae. S. agalactidiae was incubated with different concentrations of D-Arg as indicated and with A) 0 pM CATH-2; B) 1,25 pM CATH-2; C) 2,5 pM CATH-2 and D) 5 pM CATH-2 at 37 °C and growth was determined by measuring OD600every 10 min. Shown are representative curves of triplicate independent experiments.

[0132] Figure 8: CATH-2 / D-Arg is active against multiple S. aureus strains.

[0133] Colony count assays were performed on 5 S. aureus strain comparing the effect of CATH-2 alone and in combination with 5 mM D-Arg. A) S. aureus WKZ, B) S. aureus ATCC 25913, C ) S. aureus St.aul, D) S. aureus JHs-58 and E) S. aureus JHs-139. Bacteria were incubated with CATH-2 + / - 5mM D-Arg for 3 h at 37 °C Subsequently, bacterial viability was determined by plating out on TSA plates. Shown are the average + StDev of 3 independent experiments.

[0134] Figure 9: Effect of CATH-2 and D-Arg on growth of 5 S. aureus strains.

[0135] S. aureus strains A) S. aureus WKZ, B) S. aureus ATCC 25913, C) S. aureus St.aul, D) S. aureus JHs-58 and E) S. aureus JHs-139 were grown with or without 5 pM CATH-2 and / or 5 mM D-Arg at 37 °C. Growth was determined by measuring OD600every 10 min. Shown are representative curves of two independent experiments in triplicate.

[0136] Figure 10: Checkerboard assay show synergistic combinations of CATH-2 and D-Arg. S. aureus was incubated with different ratios of CATH-2 (0-80 pM) and D-Arg (0-160 mM) in 96 wells plates. After 24 h growth in each well was visually assessed and FIC indices were calculated for each combination where no growth was visible.

[0137] Figure 11: Antibacterial effect of D-Arginine and CATH-2 under anaerobic conditions. E. coli (A) and S. aureus (B) were incubated under anaerobic conditions with 5 gM CATH-2 with or without 20mM D-Arg for 3 h. At the indicated time points samples were taken and 10-fold serial dilution were made and plated onto LB agar plates. After overnight incubation at 37 °C the CFU were counted. Shown are the average + StDev of 3 independent experiments.

[0138] Figure 12: Effect of the D-Arg / CATH-2 combination on the cell permeability of Hela and Caco cells. Permeability of the Hela (A and B) and Caco cells (C and D) were investigated by LDH (A and C) and WST-1 (B and D) assays using different concentrations D-Arg and CATH-2. Shown are the average + StDev of 4 independent experiments.

[0139] Figure 13: Antibacterial activity of CATH-2 and D-Arg in raw milk. Raw milk was spiked with 1x106CFU / ml S. aureus and incubated at CATH-2 + / -D-Arg. At different time points small samples were taken and surviving bacteria enumerated by plating on TSA. Shown are the average + StDev of 3 independent experiments.

[0140] Figure 14: Checkerboard assay in raw milk medium. Raw milk was spiked with 1x106CFU / ml S. aureus and incubated with different ratios of CATH-2 (0-40 gM) and D-Arg (0-80mM) in 96 wells plates. After 24 h survival of bacteria was assessed by plating out on TSA, and FIC indices were calculated for each combination where no viable bacteria were detected.

[0141] Figure 15. Effect of CATH-2 and D-Lys on growth of S. aureus. S. aureus WKZ was grown with different concentrations of D-Lys as indicated and with A) 0 gM CATH-2; B) 1,25 gM CATH-2; C) 2,5 gM CATH-2 and D) 5 gM CATH-2. at 37 °C. Growth was determined by measuring OD600every 10 min. Shown are representative curves of two independent experiments in triplicate.

[0142] Figure 16. Checkerboard assay showing synergistic combinations of CATH-2 and D-Lys against S. aureus. S. aureus ATCC25923 was incubated with different ratios of CATH-2 (0-80 gM) and D-Lys (0-160 mM) in 96 wells plates. Growth in each well was visually assessed and by plating out wells with no growth, and FIC indices were calculated for each combination without growth.

[0143] Figure 17. Checkerboard assay showing synergistic combinations of multiple AMPs and D-Arg against S. aureus. S. aureus ATCC25923 were incubated were incubated with different ratios of AMPs (0-80 gM) and D-Arg (0-160 mM) in 96 wells plates. Growth in each well was visually assessed and by plating out wells with no growth, and FIC indices were calculated for each combination without growth. (A) LL-37, (B) CRAMP, (C) PMAP-23, (D) CATH-2 E)OH-CATH-2, F) AB-CATH, (G) FK18, (H) CATH-2(4-21), (I) DCATH-2(4-21), (J) CATH-1, (K) PMAP-36.

[0144] Figure 18. Checkerboard assay showing synergistic combinations of CATH-2 and D-Arg against other Gram-positive bacteria. L. monocytogenes (A & C), B. cereus (B & D) and S. agalactiae (E) were incubated with different ratios of CATH-2 (0-80 pM) and D-Arg (0-160 mM) (A& B) or D-Lys (0-160 mM)(C, D & E) in 96 wells plates. Growth in each well was visually assessed and by plating out wells with no growth, and FIC indices were calculated for each combination without growth.

[0145] Figure 19. Checkerboard assay showing synergistic combinations of D-Arg with AB-CATH (A), CATH-1 (B), CR-184 (C) or PMAP-36 (D) CATH-2 against E. coli. E. coli was incubated with different ratios of AMPs (0-80 pM) and D-Arg (0-160 mM) in 96 wells plates. Growth in each well was visually assessed and by plating out wells with no growth, and FIC indices were calculated for each combination without growth.

[0146] Figure 20. Checkerboard assay showing synergistic combinations of D-Arg together with FK-18, OH-CATH or AB-CATH against other Gramnegative bacteria. S. enteritidis incubated with D-Arg and FK-18 (A), OH-CATH (B) or AB-CATH (C). P. aeruginosa incubated with D-Arg and OH-CATH (D) or AB-CATH (E) and P. mirabilis incubated with D-Arg and OH-CATH(F). Bacterial strains were incubated with different ratios of AMPs (0-80 pM) and D-Arg (0-160 mM) in 96 wells plates. Growth in each well was visually assessed and by plating out wells with no growth, and FIC indices were calculated for each combination without growth.

[0147] Examples

[0148] Methods

[0149] Peptide synthesis.

[0150] Chicken cathelicidin 2 (CATH-2), RFGRFLRKIRRFRPKVTITIQGSARF, was synthesized by China Peptides (Shanghai, China) using Fmoc-chemistry. The peptide was purified by reverse phase high-performance liquid chromatography to a purity of >95%.

[0151] Chemicals.

[0152] D-amino acids used in this study were purchased from (Sigma-Aldrich Inc (Saint Louis, Missouri, US).

[0153] Bacterial strains and media

[0154] S. aureus WKZ and USA300 are multi resistant strains while S. aureus Saujes and JHs-139 were isolated from a cow with subclinical mastitis, while S. aureus JHs-58 was isolated from a cow with clinical mastitis and S. aureus ATCC25923 is a clinical isolate from a human wound infection. E.coli strain 1120-2 was isolated from a clinical mastitis case. Salmonella enterica serovar enteritidis 90-13-706, Pseudomonas aeruginosa VW170 and Proteus mirabilis were all clinical isolates. All bacteria were cultured on Luria Broth Agar plates (Thermo Scientific Oxoid, Basingstoke, UK), from which a combination of 5-10 colonies were picked for o / n growth in Luria Broth (LB, BioTRADING Benelux B. V., Mijdrecht, The Netherlands).

[0155] Colony count assays under aerobic conditions

[0156] S. aureus and E. coli cultures were grown from a fresh overnight culture to logarithmic phase in LB under constant shaking of 160 RPM at 37 °C. From logarithmic phase the bacteria were diluted to a density of 2x106CFU / ml. To 25 pl bacterial solution 25 pl LB was added containing CATH-2 (0-40 pM) and D-Arginine (0-20 mM) a polypropylene round bottom 96 wells plate. After 3 h incubation at 37 °C, serial 10-fold dilutions were prepared, which were plated on TSA plates. After o / n incubation at 37 °C, viable bacteria were counted.

[0157] Colony count assays under anaerobic conditions

[0158] Overnight cultures of S. aureus and E. coli were grown anaerobically under constant shaking of 160 RPM at 37 °C. Bacteria were diluted to a concentration of 5x105CFU / ml in LB and incubated with 20 mM D-Arg with or without 5 pM CATH-2 under anaerobic conditions. At various times during the 3-h incubation, samples were taken, serially diluted in 10-fold increments and plated on LB agar plates. After o / n incubation at 37 °C, viable bacteria were counted.

[0159] Growth curves

[0160] Growth curves of S. aureus and E. coli were recorded on a BioTek Synergy HTX Multimode Reader. In a standard assay 100 pl S. aureus with a final density of 1x106CFU / ml was added to a flatbottom 96 wells plate in the presence (or absence) of varying concentrations of CATH-2 and D-amino acids. The OD600was measured every 10 min for 24 h at 37 °C under continuous shaking.

[0161] Antibacterial activity of CATH-2 and D-Arg in milk.

[0162] In order to determine the antibacterial activity of CATH-2 and D-Arg in a relevant medium, colony count assays were performed in raw milk. S. aureus cultures were grown to logarithmic phase as described above. Subsequently fresh, raw milk was spiked with 1x106CFU / ml S. aureus and subsequently treated with D-Arg and CATH-2 from stock solutions in milliQ, (resulting in a final percentage of 85% milk, 0.2% LB and 14.8% water) and incubated at 37 °C. At varying time points small aliquots were taken from the incubation mixture, serially diluted, plated on TSA plates. These were incubated for 24 h at 37 °C and remaining viable bacteria were counted.

[0163] Determination of synergy between AMDs and D-Arg / D-Lys.

[0164] Checkerboard dilution assays were performed both in (diluted) LB and raw milk to determine possible synergy between AMPs and D-Arg / D-Lys. For the assays in LB, 1x106 CFU / ml bacteria were treated in 96 wells plates with all combinations of twofold dilutions of AMPs (0-80 pM) and D-Arg / D-Lys (0-160 mM). Visual determination of growth was performed after 24 h incubation at 37 °C and wells without visible growth were plated on TSA plates.

[0165] In raw milk a similar set-up was used but growth was only determined by plating out the incubation mixtures on TSA, because visual determining growth is impossible due to the turbidity of the milk. Separate MBC determinations for D-Arg and CATH-2 in milk were performed because they were outside of the used concentrations in the checkerboard assays. Synergy was determined by calculating the fractional inhibitory concentration index (FICI) = MIC of drug A in combination / MIC of drug A alone + MIC of drug B in combination / MIC of drug B alone. For milk the MBC of CATH-2 was 320 pM, while D-Arg did not obtain a MBC at 320 mM, but this value was used for FICI calculations. The calculated FICI was interpreted as synergistic for FICI <0.5, additive: 0.5< FICI<1; indifferent (1< FICI <4.0), or antagonistic FICI> 4.

[0166] Toxicity: WST-1 assay

[0167] To study the effect of CATH-2 and D-Arg on cell viability, Hela cells and Caco cells were seeded at a density of 2xl04cells per well in 96 well plates. These cells were subjected to various concentrations of CATH-2 and D-Arg in growth medium for 4 h. Following the incubation period, the culture medium was substituted with 100 pL of a solution containing 10% water-soluble tetrazolium 1 (WST-1) (Roche, Basel, Switzerland). Subsequent colorimetric analysis was conducted after a 10–15 min incubation period at 450 nm using a FLUOstar Omega microplate reader

[0168] (BMG Labtech GmbH, Ortenberg, Germany). Cell viability was then quantified as a percentage, with 100% indicating the viability of untreated cells.

[0169] Toxicity: LDH leakage assay

[0170] Toxicity of CATH-2 and D-Arg toward Hela and Caco cells was determined by the LDH release assay, as described previously. In short, cells were incubated with combinations of CATH-2 and D-Arg for 4 h and cytotoxicity was evaluated by measuring the proportion of LDH released into the supernatant. Cytotoxicity was expressed relative to the maximum LDH release observed in cells lysed with Triton X-100 detergent. This assessment was performed using the CytoTox 96 nonradioactive cytotoxicity kit (Promega), following the manufacturer’s instructions.

[0171] Results

[0172] Antibacterial activity of D-Amino acids.

[0173] The antimicrobial peptide CATH-2, is known to possess antibacterial activity, however its activity is strongly dependent on the present of proteases and divalent cations (Mookherjee et al., 2020). As certain D-AAs are known to enhance the effectiveness of antibiotics (Yang et al., 2024), we sought to explore whether D-amino acids could also boost the efficacy of CATH-2. Therefore we tested all soluble D-AAs in combination with or without sublethal CATH-2 whether they possess antimicrobial properties against a clinical mastitis isolate S. aureus strain JHs-58. First the final optical density of S. aureus LB cultures containing sublethal 2 uM CATH-2 with or without 20 mM D-AA was measured. No growth defect was observed when only 2 uM CATH-2 was added (Fig. 1). Of the 13 D-AA tested only D-Nor, D-Thr and D-Val slightly reduced the final optical density of the culture compared to LB alone, however when both CATH-2 and D-Lys or D-Arg were present a strong reduction of the optical density was observed, indicating that CATH-2 together with D-Lys or D-Arg are potential synergistic combinations.

[0174] Next growth curves were generated using D-Arg and D-Lys at concentrations ranging from 0 to 40 mM, with D-Ser used as a negative control to investigate whether perhaps the lag phase or higher concentration of D-Arg or D-Lys alone could influence the growth of S. aureus. At concentrations of 40 mM and 20 mM D-Arg and to a lower extend D-Lys, growth of S. aureus was inhibited as seen by the extended lag time (Fig. 2). However, this inhibitory effect was absent at lower concentrations. D-Ser showed no impact on S. aureus growth at any concentration tested.

[0175] Antibacterial activity of CATH-2 in combination with D-Arg

[0176] To address how D-Arg together with CATH-2 influence the growth of S. aureus we generated growth curves using varying concentrations CATH-2 (0-5 pM) and D-arg (0 to 20 mM)(Fig. 3). We observed that by increasing the amount of D-Arg in the presence of CATH-2, not only the lag phase extended, but also the slope and to a lower extend the final optical density was reduced. This suggest that it takes longer before the bacteria have been adapted to the culture medium and that uptake of nutrients is slower in the presence of D-Arg and CATH-2. No growth was observed with 2.5 pM CATH-2 with 20 mM D-Arg or 5 pM CATH-2 with 5, 10 or 20 mM D-Arg.

[0177] To explore the effects of combined treatment with CATH-2 and D-Arg on the survival of S. aureus, colony count assays were performed using different concentrations of D-Arg (0-20 mM) and CATH-2 (0-40) pM (Fig. 4). As depicted in Fig. 4, CATH-2 was weakly active against S. aureus with a 2-log reduction of viable bacteria at the highest concentration tested (40 pM). Addition of 5 mM or higher concentrations of D-Arg had a strong concentration- dependent positive effect on the antibacterial activity of CATH-2 leading to MBC values of 10 pM and lower. These results indicate that a large amount of S. aureus bacteria are killed when incubated with CATH-2 and D-Arg.

[0178] To investigate whether the D-Arg / CATH-2 combination also had an effect on another mastitis causing bacteria, E. coli, we generated growth curves using varying concentrations CATH-2 (0-5 pM) and D-Arg (0 to 20 mM)(Fig. 5). In contrast to S. aureus, increasing the concentration of CATH-2 alone strongly extended the lag phase of E. coli. The addition of D-Arg alone hardly affected the growth of E. coli. In combination with CATH-2, D-Arg resulted in a mild reduced growth effect.

[0179] To investigate whether the D-Arg / CATH-2 combination also had an effect on bacteria S. uberis and S. agalactidiae we generated growth curves using varying concentrations CATH-2 (0-5 pM) and D-Arg (0 to 20 mM)(Fig. 6 and 7). Although higher concentrations of CATH-2 alone reduce bacterial growth, its combination with D-Arg completely inhibited the growth of both S. uberis (Fig. 6) and S. agalactidiae (Fig. 7), even at the lowest concentrations of D-Arg.

[0180] To rule out strain-specificity of the observed antibacterial effect of the CATH-2 / D- Arg combinations, we subsequently tested 5 different S. aureus strains. The strains included multi-resistant strain S. aureus WKZ and 2 clinical strains isolated from cows with mastitis (JHs-58 and JHs-139). As shown in Fig. 5A 5 mM D-Arg increased activity of CATH-2 in all strains. Similar effects were seen in thegrowth curves (Fig. 9) where 5 mM D-Arg, despite having no antibacterial effect on its own substantially increased CATH-2’s activity.

[0181] Detection of synergy between CATH-2 and D-Arg.

[0182] To investigate whether CATH-2 and D-Arg exhibit a synergistic effect, a checkerboard assay in LB was performed (Fig. 10). The minimum inhibitory concentration of D-Arg and CATH-2 that prevented growth of S. aureus was 20 mM and 20 pM, respectively. Synergy was determined by calculating the fractional inhibitory concentration index (FICI), FIC indices ranged from 0.375 – 0.625 for specific ratios of CATH-2 and D-Arg. For example, the combination of 5 pM CATH-2 and 5 mM D-Arg resulted in no growth and a resulting FIC index of 0.375, while other ratio’s such as 1.25 pM CATH-2 + 20 mM D-Arg resulted in a FIC index just above 0.5. These results show that CATH-2 and D-Arg are synergistic in nature.

[0183] Synergistic activity of D-Arg and CATH-2 under anaerobic conditions.

[0184] Because mastitis leads to a dramatic drop in the oxygen concentration we investigated whether D-Arg / CATH-2 combination also works under anaerobic conditions. Here for S. aureus and E. coli were incubated under anaerobic conditions with 20 mM D-Arginine, with or without 5 pM CATH-2 (Fig. 11). As observed under aerobic conditions E. coli was highly sensitive to CATH-2 alone, and the combination D-Arg and CATH-2 resulted in a mild additional reduction of CFU. However similar to aerobic conditions only the D-Arg / CATH-2 combination killed all the S. aureus bacteria. The time to eliminate all S. aureus bacteria was even shorter under anaerobic compared to aerobic conditions.

[0185] Toxicity.

[0186] To investigate whether the D-Arg / CATH-2 combination is not toxic for eukaryotic cells, WST and LDH assays were performed on Hela (12 A & B) and Caco (12 C & D) cells (Fig 12). Hela or Caco cells were incubated for 4 h with different concentrations of CATH-2 and D-Arg. As shown in Fig. 12, the addition of D-Argine has no effect on the toxicity. However, toxicity was observed for the Hela cells when CATH-2 concentrations exceeded 10 pM, but not for the Caco cells.

[0187] Activity of CATH-2 and D-Arg in raw milk.

[0188] Since milk is the envisioned environment for treatment of mastitis, the antibacterial activity of CATH-2 in the presence and absence of D-Arg was tested in freshly obtained raw milk spiked with S. aureus. This was assessed through colony-forming unit (CFU) counting to measure bacterial survival. InterestinglyCATH-2 lost its antibacterial effect in milk (Fig.13) likely through activityinhibiting components in the milk. Similarly, D-Arg alone had no effect on the survival of the spiked S. aureus (not shown). However, when both were combined a strong reduction in the number of viable bacteria was seen. At 5 pM CATH-2 and 20 mM D-Arg > 31og reduction in CFU / ml was achieved within 3 h, while 10 pM CATH-2 and 20 mM D-Arg led to complete eradication of all bacteria (Fig. 13 top and bottom). Increasing the concentration of D-Arg further to 40 mM showed even faster kinetics of killing. These results clearly indicate the potential of CATH-2 and D-Arg to kill S. aureus from raw milk.

[0189] Determination of synergy in raw milk.

[0190] To determine whether CATH-2 and D-Arg also exhibit a synergistic effect in raw milk, a checkerboard assay was performed. Since visual end-point registration is impossible in milk each well was plated out on TSA plates to detect viable bacteria. A representative example is shown in Fig. 14 and shows that combinations starting from 10 pM CATH-2 or 10 mM D-Arg resulted in complete killing of bacteria leading to FICI values between 0.1 and 0.3, all indicating strong synergy for these components in milk.

[0191] Effect of D-Lys and CATH-2 on growth of S. aureus.

[0192] To determine that D-Lys had similar activating effects on CATH-2 as D-Arg growth curves were made of S. aureus in the presence of CATH-2 and D-Lys. As shown in Fig. 15, low concentrations of D-Lys indeed increased the effect of CATH-2. For example, a concentration of 5 mM D-Lys, which has no effect on growth on its own, significantly increased the lag time with more than 10 h when combined with 2.5 pM CATH-2 (Fig 15. C), and lowered the slope of the growth curve in the exponential growth phase.

[0193] Antibacterial activity of D-Lys is also synergistic with CATH-2.

[0194] To investigate whether CATH-2 and D-Lys exhibit a synergistic effect against S. aureus, a checkerboard assay in LB was performed (Fig. 16). The minimum inhibitory concentration of D-Lys and CATH-2 that prevented growth of S. aureus was 160 mM and 20 pM, respectively. Strong synergy was observed with 10 mM D-Lys and 0,625 pM CATH-2, resulting in a FIC indices of 0.09. These results showed that, similar to D-Arg, also D-Lys acted synergistically with CATH-2 against S. aureus.

[0195] Antibacterial activity of D-Arg is synergistic with a broad range of AMPs.

[0196] In order to investigate if the synergistic effect of the combination of CATH-2 and D-Arg was specific to this AMP, a set of linear cationic peptides were tested for their synergy with D-Arg in killing S. aureus using checkerboard assays. As shown in Fig. 17, a large number of peptides, including cathelicidins from human, pig and mouse, but also a designed peptide (FK18) were indeed synergistic with D-Arg showing FIC indexes under 0.5 for a range of combined concentrations of the 2 components. This indicates that synergy between AMPs and D-Arg in killing S. aureus is a general feature of many AMPs.

[0197] Synergy between CATH-2 and D-Arg is not restricted to S. aureus.

[0198] In order to determine if the synergistic antibacterial effect of CATH-2 and D-Arg was restricted to S. aureus, other Gram-positive bacteria were tested in checkerboard assays for their susceptibility towards CATH-2 I D-Arg. As shown in Fig. 18, the combination of CATH-2 and D-Arg also showed a synergistic antibacterial activity towards Listeria monocytogenes and Bacillus cereus. In addition, the combination of CATH-2 and D-Lysine was tested and it was shown that also D-Lysine acted synergistically with CATH-2 against the Gram-positive bacteria L. monocytogenes, B. cereus and Streptococcus agalactiac.

[0199] Combinations of antimicrobial peptides and D-Arg are synergistically antibacterial against Gram-negative bacteria.

[0200] Similar to the experiments with S. aureus multiple AMPs were tested in checkerboard assays for their synergistic antibacterial effect against E coli.

[0201] Combinations of AB-CATH, CATH-1, CR-184 and PMAP-36 indeed showed FIC indexes below 0.5 indicating synergy (Fig. 19). In addition, OH-CATH, AB-CATH and FK18 showed synergy with D-Arg against Salmonella enteritidis and Pseudomonas aeruginosa, while OH-CATH also showed strong synergy with D-Arg against Proteus Mirabilis (Fig 20).

[0202] References

[0203] Alvarez, L., Aliashkevich, A., de Pedro, M. A., & Cava, F. (2018). Bacterial secretion of D-arginine controls environmental microbial biodiversity. The ISME journal, 12(2), 438-450.

[0204] Lam, H., Oh, D. C., Cava, F., Takacs, C. N., Clardy, J., de Pedro, M. A., et al. (2009). D-amino acids govern stationary phase cell wall remodeling in bacteria. Science 18;325(5947):1552-1555.

[0205] Mookherjee, N., Anderson, M. A., Haagsman H. P., Davidson D. J. (2020).

[0206] Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 19(5):311-332.

[0207] Yang, J., Ran, Y., Liu, S., Ren, C., Lou, Y., Ju, P., Li, G., Li, X., Zhang, D. (2024). Synergistic D-Amino Acids Based Antimicrobial Cocktails Formulated via

[0208] High-Throughput Screening and Machine Learning. Adv Sci (Weinh) 11:e2307173.

Claims

Claims1. A combination of an antimicrobial peptide and a positively charged D-amino acid for use in the treatment or prevention of a bacterial infection in a subject, wherein the antimicrobial peptide is a cationic u-helical antimicrobial peptide and the positively charged D-amino acid is selected from D-arginine, D-lysine or a combination thereof.

2. A method for the treatment or prevention of a bacterial infection in a subject, comprising administering to the subject a combination of an antimicrobial peptide and a positively charged D-amino acid, wherein the antimicrobial peptide is a cationic u-helical antimicrobial peptide and the positively charged D-amino acid is selected from D-arginine, D-lysine or a combination thereof.

3. The combination or method according to any one of the preceding claims, wherein the antimicrobial peptide is a cathelicidin.

4. The combination or method according to any one of the preceding claims, wherein the antimicrobial peptide exerts antibacterial activity by interacting with negatively charged bacterial membrane thereby increasing membrane permeability.

5. The combination or method according to any one of the preceding claims, wherein the antimicrobial peptide is selected from the group consisting of PMAP-36, CATH-2, chicken CATH-1, chicken CATH-3, OH-CATH, AB-CATH and a derivative of any thereof.

6. The combination or method according to claim 5, wherein the derivative of an antimicrobial peptide is a C-terminally and / or N-terminally truncated derivative, a D-amino acid derivative, or a C-terminally or N-terminally truncated D-amino acid derivative of said antimicrobial peptide.

7. The combination or method according to any one of the preceding claims, wherein the antimicrobial peptide is CATH-2 or PMAP-36.

8. The combination or method according to any one of the preceding claims, wherein the bacterial infection is infection by a gram-positive bacterium or by Escherichia coli.

9. The combination or method according to any one of the preceding claims, wherein the bacterium is selected from the group consisting of Escherichia coli, Staphylococcus aureus, Streptococcus uberis, Streptococcus agalactiae, Streptococcus pneumoniae, Pseudomonas aeruginosa, Heamophilus influenzae, Klebsiella pneumoniae, Proteus mirabilis and any combination thereof, preferably wherein the bacterium is selected from the group consisting of Staphylococcus aureus, Streptococcus uberis, Streptococcus agalactiae, and any combination thereof.

10. The combination or method according to any one of claims 1-8, wherein the bacterium is selected from the group consisting of Staphylococcus aureus, Bacillus cereus, Streptococcus uberis, Streptococcus agalactiae, Listeria monocytogenes, Escherichia coli and any combination thereof.

11. The combination or method according to any one of the preceding claims, wherein the bacterial infection is selected from intramammary infection, preferably mastitis, urinary tract infection, dermatitis, eye infection, ear infection, venereal infection, and respiratory tract infection.

12. The combination or method according to claim 11, wherein the infection is caused by a bacterium selected from the group consisting of Staphylococcus aureus, including multi-drug resistant S. aureus, non-aureus staphylococci and mammaliicocci (including Staphylococcus chromogenes, Staphylococcus heamolyticus, Staphylococcus epidermidis, Staphylococcus simulans, Staphylococcus equorum, Staphylococcus warneri, Staphylococcus cohnii, Staphylococcus hominis, Staphylococcus capitis, Staphylococcus xylosis, Staphylococcus lugdunensis, Staphylococcus caprae, Mammaliicoccus sciuri, Mammaliicoccus fleurettii, Mammaliicoccus lentus and other Staphylococcus spp. and Mammaliicoccus spp.), Streptococcus uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus canis, Trueperella pyogenes, Corynebacterium bovis and other Corynebacterium spp., Klebsiella oxytoca, Klebsiella pneumoniae and other Klebsiella spp., Mycoplasma bovis and other spp., Pseudomonas aeruginosa and other Pseudomonas spp., Serratia marcescens and other Serratia spp., Mannheimia haemolytica, Enterococcus saccharolyticus, Enterococcus faecium, Enterococcus cecorum and other Enterococcus spp., Bacillus cereus and other Bacillus spp., Listeria monocytogenes and combinations thereof.

13. The combination or method according to any one of the preceding claims, wherein the antimicrobial peptide is administered in a sub-effective dose based on monotherapy and the positively charged D-amino acid is administered in a subeffective dose based on monotherapy, in particular wherein the sub-effective dose of the antimicrobial peptide and the sub-effective dose of the positively charged D-amino acid have a synergistic effect upon co -administration.

14. The combination or method according to any one of the preceding claims, wherein the antimicrobial peptide is administered in a concentration of 20 μM or lower, preferably 10 μM or lower, and the positively charged D-amino acid is administered in a concentration of 40 mM or lower, preferably 20 mM or lower.

15. The combination or method according to any one of the preceding claims, wherein the subject is selected from the group consisting of livestock animals.

16. The combination or method according to any one of the preceding claims, wherein the bacterial infection is an intramammary infection, preferably mastitis, and the antimicrobial peptide and positively charged D-amino acid are administered intramammary.

17. The combination according to any one of claims 1-15, wherein the bacterial infection is a urinary tract infection and the antimicrobial peptide and positively charged D-amino acid are administered by cystocentesis or urethral catheterization.

18. A pharmaceutical composition comprising an antimicrobial peptide, a positively charged D-amino acid and a pharmaceutically acceptable carrier and / or excipient, wherein the antimicrobial peptide is a cationic u-helical antimicrobial peptide and the positively charged D-amino acid is selected from D-arginine, D-lysine or a combination thereof.

19. A kit of parts comprising a pharmaceutical composition comprising an antimicrobial peptide and a pharmaceutically acceptable carrier and / or excipient, and a pharmaceutical composition comprising a positively charged D-amino acid and a pharmaceutically acceptable carrier and / or excipient wherein the positively charged D-amino acid is preferably D-arginine or D-lysine and the antimicrobial peptide is preferably as defined in any one of claims 3-5.

20. The pharmaceutical composition or kit of parts according to claim 18 or 19 wherein the antimicrobial peptide is a cathelicidin.

21. The pharmaceutical composition or kit of parts according to any one of claims 18-20, wherein the antimicrobial peptide exerts antibacterial activity by interacting with negatively charged bacterial membrane thereby increasing membrane permeability.

22. The pharmaceutical composition or kit of parts according to any one of claims 18-21, wherein the antimicrobial peptide is selected from the group consisting of PMAP-36, CATH-2, chicken CATH-1, chicken CATH-3, OH-CATH, AB-CATH and a derivative of any thereof.

23. The pharmaceutical composition or kit of parts according to claim 22, wherein the derivative of an antimicrobial peptide is a C-terminally and / or N-terminally truncated derivative, a D-amino acid derivative, or a C-terminally or N-terminally truncated D-amino acid derivative of said antimicrobial peptide.